REPRIEVE Trial Results Have Been Incorporated Into the 2026 AHA/ACC Clinical Guidelines!

The primary results of the REPRIEVE Trial are now available online and show that pitavastatin calcium lowers the incidence rate of heart disease events by 36% in people with HIV. In March 2026, the American College of Cardiology/American Heart Association released recommendations for the use of statin therapy in people with HIV. Click here to read the updated guidelines! Click here to read a commentary supporting REPRIEVE's results in the 2026 multi-society clinical guidelines, written by REPRIEVE investigators!

REPRIEVE Facts

Bottle-Icon
REPRIEVE evaluated if a statin medication (pitavastatin calcium) is effective to prevent heart disease among people with HIV.
Heart-Pulse-Icon
REPRIEVE was the largest randomized trial to date in HIV and results from REPRIEVE are helping clinical researchers and clinical care providers to develop heart disease prevention and treatment guidelines, specifically for people with HIV.
Number of Participants
7769

Percentage of Women
31%

Mean Age
50

Mean Years Living with HIV
13

Manuscripts Published
70

Retention-Graphic-HOME

Read more about what we’re learning in REPRIEVE

REPRIEVE Publications
REPRIEVE-Promo-Logo-768px

Click here to read about REPRIEVE in the news!

REPRIEVE News

Over 7500 Participants Joined REPRIEVE!

Here are two of their stories.

REPRIEVE was a representative study

There were over 100 clinical sites in 12 countries around the world

Supporting Organizations